<?xml version="1.0" encoding="UTF-8"?>
<snippetsTree>
 <snippets file="dict8/PMC7423094/results/search/testTrace/results.xml">
  <result pre="recuperated from an infection, and administered to patients with the" exact="infection" post="in order to improve clinical outcome [6]. Although the"/>
  <result pre="patients with severe COVID-19 and the mainstay of current clinical" exact="treatment" post="consisting of symptomatic management and mechanical ventilation, administering convalescent"/>
  <result pre="of symptomatic management and mechanical ventilation, administering convalescent plasma for" exact="treatment" post="purposes is currently being deployed [7–12]. Although it is"/>
  <result pre="Medicine for his work, which served as a basis for" exact="treatment" post="of multiple diseases in the 1900s as well as"/>
  <result pre="notion that convalescent plasma could be a viable option for" exact="treatment" post="of COVID-19 patients, particularly upon early administration [6, 9,"/>
  <result pre="antibodies from the blood of someone who recovered from an" exact="infection" post="can be administered to protect or treat another person"/>
  <result pre="case of prophylaxis, a subject considered at high risk for" exact="infection" post="(because of age or underlying medical conditions or who"/>
  <result pre="can be administered to treat subjects who have contracted the" exact="infection" post="but have not made sufficient antibodies against the virus"/>
  <result pre="who recovered from COVID-19 can be administered prophylactically to prevent" exact="infection" post="in vulnerable individuals and those with known exposure to"/>
  <result pre="antibody-dependent enhancement (ADE), whereby antibodies that developed during a prior" exact="infection" post="exacerbate severity of the disease [12, 28]. The transfer"/>
  <result pre="recruitment of proinflammatory cytokines and chemokines to the site of" exact="infection" post="and causing severe tissue damage [29–31]. Additionally, the presence"/>
  <result pre="low because of strict transfusion protocols, and when used for" exact="treatment" post="purposes, the recipient is already infected [12, 36]. The"/>
  <result pre="to develop convalescent plasma therapy into a viable (albeit short-term)" exact="treatment" post="option particularly for the critically ill. Although its efficacy"/>
  <result pre="focused not only on evaluation of the feasibility of plasma" exact="treatment" post="for infectious diseases but also ensure that use of"/>
  <result pre="Epub 2020/04/16. 10.1002/jmv.25577 .31502247 11SheridanC.Convalescent serum lines up as first-choice" exact="treatment" post="for coronavirus. Nat Biotechnol. 2020;(38):655–658. Epub 2020/05/03. 10.1038/d41587-020-00011-1 .32358594"/>
  <result pre="Experimental Streptococcal Arthritis. J Infect Dis. 1914;15(1):215–26. 17Smith DD. Serum" exact="treatment" post="of scarlet fever [doctoral thesis]. Omaha (Nebraska): University of"/>
  <result pre="of Nebraska; 1934. 18The use of convalescent serum in the" exact="treatment" post="of measles, chickenpox, mumps and whooping cough, including the"/>
  <result pre="1938;111(26):2361–4. 10.1001/jama.1938.02790520017004 20CasadevallA, ScharffMD. Serum therapy revisited: animal models of" exact="infection" post="and development of passive antibody therapy. Antimicrob Agents Chemother."/>
  <result pre="WintersJL, et al.Deployment of convalescent plasma for the prevention and" exact="treatment" post="of COVID-19. J Clin Invest. 2020 Epub 2020/04/08. 10.1172/JCI138745"/>
  <result pre=".32254064 22HungIF, ToKK, LeeCK, LeeKL, ChanK, YanWW, et al.Convalescent plasma" exact="treatment" post="reduced mortality in patients with severe pandemic influenza A"/>
  <result pre="LiPH, CheungCY, DutryI, LiD, et al.Antibody-dependent enhancement of SARS coronavirus" exact="infection" post="and its role in the pathogenesis of SARS. Hong"/>
 </snippets>
</snippetsTree>
